ΜΑΝΟΛΗΣ ΣΙΝΑΚΟΣ

Δημοσιεύσεις

1: Liava C, Chourmouzi D, Gioula G, Sinakos E, Akriviadis E. Clinical associations, outcomes, and therapeutic management of patients with symptomatic sclerosing mesenteritis. Ther Adv Gastroenterol. 2026 Aug 4;19:17562848261475954. doi: 10.1177/17562848261475954. PMID: 42559012; PMCID: PMC13438346.

2: Kavvadas D, Pentara NV, Kourdakis D, Liakos A, Sinakos E, Prassopoulos P, Rafailidis V. Diagnostic Performance of Ultrasound-Guided Attenuation Parameter (UGAP) for Hepatic Steatosis Assessment: Comparison with MRI-PDFF and Evaluation of Cohort-Derived Thresholds. Diagnostics (Basel). 2026 Jun 27;16(13):2006. doi: 10.3390/diagnostics16132006. PMID: 42449788; PMCID: PMC13359665.

3: Xu X, Shi Y, Tacke F, Wai-Sun Wong V, Li W, Sebastiani G, Newsome PN, Romero- Gomez M, Pan C, Castera L, Chai J, Kim W, Valenti L, Yilmaz Y, Win KM, Xu X, Ocama P, Ghazinyan H, Al Mahtab M, Hamid S, Lesmana CRA, Romeo S, Castellanos Fernandez MI, Yu X, Luukkonen PK, Takahashi H, Charatcharoenwitthaya P, Boursier J, Cua IH, Dao HV, Spearman CW, Bandara Dassanayake SU, Ayurzana M, Aghayeva G, Muthiah MD, Mendez-Sanchez N, Stedman CA, Alswat K, Sharara AI, Debzi N, Leite NC, Alkhatry MS, van Kleef LA, Barakat S, Al-Busafi SA, Agyei-Nkansah A, Fouad Y, Gracia-Sancho J, Lupsor-Platon M, Ryan JD, Chan WK, Cortez-Pinto H, Mandorfer M, Duseja A, Papatheodoridis G, Francque SM, Byrne CD, Targher G, George J, Zheng MH; Global Hepatology Training Consortium. Delphi survey to explore core curriculum for training the next generation of hepatologists. JHEP Rep. 2026 Sep;8(9):101942. doi: 10.1016/j.jhepr.2026.101942. Epub 2026 Jul 8. PMID: 42419486; PMCID: PMC13482606.

4: Lakiotaki D, Papatheodoridi M, Sevastianos V, Zachou K, Christodoulou D, Koskinas J, Deutsch M, Alexopoulou A, Elefsiniotis I, Triantos C, Gigi E, Androutsakos T, Karagiannakis DS, Mani I, Dimitroulopoulos D, Mela M, Sinakos E, Michopoulos S, Mimidis K, Papadopoulos N, Kontos A, Veretanos C, Lymperopoulos D, Giannoulis G, Papadimitropoulos V, Avramopoulou E, Papatheodoridi A, Pantzios S, Vasilieva L, Kranidioti H, Koullias E, Soukovelos A, Fytili P, Vlachogiannakos J, Cholongitas E, Manolakopoulos S, Goulis I, Dalekos G, Papatheodoridis G. HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D. J Viral Hepat. 2026 Jul;33(7):e70201. doi: 10.1111/jvh.70201. PMID: 42322023; PMCID: PMC13282446.

5: Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, Terrault N, Nguyen H, Yim HJ, Xie Q, Lin J, Qiu Y, Jeng WJ, Heo J, Peng CY, Chen CH, Chuang WL, Xie Y, Hlebowicz M, Idriz N, Mehta R, Agarwal K, Gomes da Silva MM, Franca A, Cernat R, Leerapun A, Coffin CS, Gadano A, Andreone P, Fujiyama S, Sevastianos V, Suzuki Y, Ratziu V, Riachi G, Stocker H, Lim TH, Asselah T, Tanaka Y, Holmes J, Liang X, Cremer J, Lukić T, Plein H, Quinn G, Tao Y, Paff M, Theodore D, Elston R; B-Well Study Group. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Engl J Med. 2026 Jun 25;394(24):2395-2406. doi: 10.1056/NEJMoa2515131. Epub 2026 May 28. PMID: 42206582.

6: Liava C, Chourmouzi D, Sinakos E, Gioula G, Akriviadis E. Natural history, clinical associations, and management issues of idiopathic sclerosing mesenteritis: a prospective cohort study. Gastroenterol Rep (Oxf). 2026 Apr 25;14:goag035. doi: 10.1093/gastro/goag035. PMID: 42038200; PMCID: PMC13109999.

7: Malandris K, Charalampidis K, Loomba R, Sinakos E. Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. Curr Diab Rep. 2026 Mar 14;26(1):6. doi: 10.1007/s11892-026-01621-w. PMID: 41831086; PMCID: PMC12989002.

8: Vasileiadou S, Antoniadis N, Fylaktou A, Neiros S, Karageorgos FF, Stangou M, Sinakos E, Kotoulas SC, Massa E, Mouloudi E, Tsoulfas G. Diagnostic and Prognostic Value of Donor-Derived Cell-Free DNA in Acute Rejection After Kidney Transplantation: A Narrative Review. Diagnostics (Basel). 2026 Feb 26;16(5):668. doi: 10.3390/diagnostics16050668. PMID: 41827944; PMCID: PMC12984478.

9: Karapanagiotidi F, Boutari C, Sinakos E. Genetic Predisposition to MASLD: Potential for Therapeutic Management. Int J Mol Sci. 2026 Feb 18;27(4):1933. doi: 10.3390/ijms27041933. PMID: 41752069; PMCID: PMC12940723.

10: Papagiouvanni I, Theodorakopoulou M, Protopapas AA, Dimitroulas T, Doumas M, Sinakos E, Sarafidis P, Goulis I. Capillary microvascular function in patients with liver cirrhosis: a nailfold video-capillaroscopy study. Ann Gastroenterol. 2026 Jan-Feb;39(1):23-31. doi: 10.20524/aog.2026.1030. Epub 2025 Dec 15. PMID: 41612992; PMCID: PMC12850683.

11: Malandris K, Katsoula A, Nayfeh T, Tsapa K, Tsapa D, Kalopitas G, Liakos A, Karagiannis T, Theocharidou E, Sinakos E, Germanidis G, Tsapas A. Magnetic resonance elastography combined with fibrosis-4 index for diagnosing at-risk metabolic dysfunction-associated steatohepatitis: a systematic review and meta- analysis of diagnostic test accuracy studies. Ann Gastroenterol. 2025 Nov- Dec;38(6):681-690. doi: 10.20524/aog.2025.1010. Epub 2025 Oct 10. PMID: 41586394; PMCID: PMC12829540.

12: Markoutsaki V, Dimakopoulos G, Sinakos E, Kotsa K, Koufakis T. Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus. Hormones (Athens). 2025 Dec 19. doi: 10.1007/s42000-025-00743-2. Epub ahead of print. PMID: 41417204.

13: Kavvadas D, Rafailidis V, Liakos A, Sinakos E, Partovi S, Papamitsou T, Prassopoulos P. Quantitative Ultrasound for Hepatic Steatosis: A Systematic Review Highlighting the Diagnostic Performance of Ultrasound-Derived Fat Fraction. Diagnostics (Basel). 2025 Oct 20;15(20):2640. doi: 10.3390/diagnostics15202640. PMID: 41153312; PMCID: PMC12562858.

14: Boutari C, Triantafyllou A, Papalavrentios L, Goulis I, Sinakos E. FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data. Curr Pharm Des. 2026;32(20):1552-1566. doi: 10.2174/0113816128374854250709050425. PMID: 40765085.

15: Verrou E, Diamanti I, Fylaktou A, Daiou A, Dalampira D, Dimitriadou X, Tara V, Karadrakonti E, Triantafyllou T, Sevastoudi A, Vlachaki E, Karampatzakis N, Papadopoulou T, Sinakos E, Katodritou E, Gioula G. Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon? Front Oncol. 2025 Jun 24;15:1586454. doi: 10.3389/fonc.2025.1586454. PMID: 40630201; PMCID: PMC12234450.

16: Papatheodoridi M, Sevastianos V, Zachou K, Christodoulou D, Koskinas J, Deutsch M, Alexopoulou A, Elefsiniotis I, Triantos C, Gigi E, Androutsakos T, Karagiannakis D, Mani I, Dimitroulopoulos D, Mela M, Sinakos E, Michopoulos S, Mimidis K, Papadopoulos N, Kontos A, Veretanos C, Lymperopoulos D, Giannoulis G, Papadimitropoulos V, Avramopoulou E, Papatheodoridi A, Pantzios S, Vasilieva L, Kranidioti H, Koullias E, Psychos N, Fytili P, Vlachogiannakos J, Cholongitas E, Manolakopoulos S, Goulis I, Dalekos G, Papatheodoridis G. HERACLIS_BLV_D: Increasing Response Rates During 2-Year Bulevirtide Real-Life Therapy in Chronic Hepatitis D. Liver Int. 2025 Jul;45(7):e70151. doi: 10.1111/liv.70151. PMID: 40522200; PMCID: PMC12169071.

17: Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PMID: 40305708.

18: Liava C, Chourmouzi D, Sinakos E, Dimitroulas T, Navrozidou C, Akriviadis E. Prevalence, Clinical Features, and Extraintestinal Manifestations in Patients with Familial Inflammatory Bowel Diseases. Dig Dis Sci. 2025 Apr;70(4):1467-1476. doi: 10.1007/s10620-025-08868-5. Epub 2025 Feb 13. PMID: 39946067; PMCID: PMC11972201.

19: Malandris K, Korakas E, Sarakapina A, Kalopitas G, Iatridi F, Liakos A, Bekiari E, Giouleme O, Tzatzagou G, Karagiannis T, Paschos P, Vasilakou D, Lambadiari V, Tzamou E, Daravigkas D, Sinakos E, Tsapas A. Accuracy of Controlled Attenuation Parameter for Liver Steatosis in High-Risk Patients for MASLD Using MRI-Proton Density Fat Fraction as Reference Standard. Dig Dis Sci. 2025 Feb;70(2):814-824. doi: 10.1007/s10620-024-08799-7. Epub 2024 Dec 21. PMID: 39708259.

20: Malandris K, Katsoula A, Liakos A, Karagiannis T, Sinakos E, Giouleme O, Klonizakis P, Theocharidou E, Gigi E, Bekiari E, Tsapas A. Diagnostic accuracy of Agile-4 score for liver cirrhosis in patients with metabolic dysfunction- associated steatotic liver disease. A systematic review and meta-analysis of diagnostic test accuracy studies. Diabetes Obes Metab. 2025 Mar;27(3):1406-1414. doi: 10.1111/dom.16142. Epub 2024 Dec 20. PMID: 39703127; PMCID: PMC11802403.

21: Malandris K, Arampidis D, Mainou M, Papadopoulos N, Karagiannis T, Nayfeh T, Liakos A, Sinakos E, Tsapas A, Bekiari E. FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and meta-analysis of diagnostic test accuracy studies. J Gastroenterol Hepatol. 2024 Dec;39(12):2582-2591. doi: 10.1111/jgh.16770. Epub 2024 Oct 12. PMID: 39394945; PMCID: PMC11660209.

22: Malandris K, Katsoula A, Liakos A, Bekiari E, Karagiannis T, Theocharidou E, Giouleme O, Sinakos E, Tsapas A. Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis. Ann Gastroenterol. 2024 Sep-Oct;37(5):579-587. doi: 10.20524/aog.2024.0910. Epub 2024 Aug 19. PMID: 39238800; PMCID: PMC11372538.

23: Fragkou N, Vlachaki E, Goulis I, Sinakos E. Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease. World J Hepatol. 2024 May 27;16(5):671-677. doi: 10.4254/wjh.v16.i5.671. PMID: 38818299; PMCID: PMC11135276.

24: Malandris K, Papandreou S, Vasilakou D, Kakotrichi P, Sarakapina A, Kalopitas G, Karagiannis T, Giouleme O, Bekiari E, Liakos A, Iatridi F, Paschos P, Sinakos E, Tsapas A. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. J Gastroenterol Hepatol. 2024 Jul;39(7):1219-1229. doi: 10.1111/jgh.16559. Epub 2024 Apr 16. PMID: 38627972.

25: Cholongitas E, Oikonomou T, Bafa K, Sinakos E, Papatheodoridis GV, Goulis I. Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients. Transplantation. 2024 Sep 1;108(9):e239-e244. doi: 10.1097/TP.0000000000005027. Epub 2024 Apr 1. PMID: 38557857.

26: Sinakos E, Kachru N, Tsoulas C, Jeyakumar S, Smith NJ, Yehoshua A, Cholongitas E. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece. J Comp Eff Res. 2024 Apr;13(4):e230090. doi: 10.57264/cer-2023-0090. Epub 2024 Feb 6. PMID: 38317634; PMCID: PMC11044955.

27: Malandris K, Papandreou S, Avgerinos I, Karagiannis T, Paschos P, Michailidis T, Liakos A, Bekiari E, Sinakos E, Tsapas A. Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis. Hormones (Athens). 2023 Dec;22(4):655-664. doi: 10.1007/s42000-023-00493-z. Epub 2023 Sep 28. PMID: 37770761; PMCID: PMC10651545.

28: Liava C, Ouranos K, Chatziioannou A, Kamenidou I, Kofinas A, Vasileiadou S, Antoniadis N, Katsanos G, Akriviadis E, Sinakos E. Impact and management of COVID-19 in liver transplant candidates and recipients. Ann Gastroenterol. 2023 Sep-Oct;36(5):477-489. doi: 10.20524/aog.2023.0815. Epub 2023 Jul 3. PMID: 37664224; PMCID: PMC10433260.

29: Kalopitas G, Mouskeftara T, Liapikos T, Arvanitakis K, Ioannidis A, Malandris K, Theocharidou E, Chourdakis M, Sinakos E, Gika H, Germanidis G. Plasma Lipids Profile in the Prediction of Non-Alcoholic Steatohepatitis in Adults: A Case-Control Study. Int J Mol Sci. 2023 Aug 12;24(16):12717. doi: 10.3390/ijms241612717. PMID: 37628898; PMCID: PMC10454013.

30: Pantelidou P, Sinakos E, Germanidis G, Pagkalidou E, Haidich AB, Akriviadis E, Hytiroglou P. Assessment of histologic risk factors for hepatocellular carcinoma in patients with chronic hepatitis B of advanced stage. Pathol Res Pract. 2023 Sep;249:154741. doi: 10.1016/j.prp.2023.154741. Epub 2023 Aug 5. PMID: 37586217.

31: Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant. 2022 Nov 18;12(11):331-346. doi: 10.5500/wjt.v12.i11.331. PMID: 36437845; PMCID: PMC9693898.

32: Oikonomou IM, Sinakos E, Antoniadis N, Goulis I, Giouleme O, Anifanti M, Katsanos G, Karakasi KE, Tsoulfas G, Kouidi E. Effects of an active lifestyle on the physical frailty of liver transplant candidates. World J Transplant. 2022 Nov 18;12(11):365-377. doi: 10.5500/wjt.v12.i11.365. PMID: 36437844; PMCID: PMC9693895.

33: Liava C, Sinakos E, Papadopoulou E, Giannakopoulou L, Potsi S, Moumtzouoglou A, Chatziioannou A, Stergioulas L, Kalogeropoulou L, Dedes I, Akriviadis E, Chourmouzi D. Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview. World J Gastroenterol. 2022 Aug 28;28(32):4540-4556. doi: 10.3748/wjg.v28.i32.4540. PMID: 36157932; PMCID: PMC9476877.

34: Papagiouvanni I, Sarafidis P, Theodorakopoulou MP, Sinakos E, Goulis I. Endothelial and microvascular function in liver cirrhosis: an old concept that needs re-evaluation? Ann Gastroenterol. 2022 Sep-Oct;35(5):471-482. doi: 10.20524/aog.2022.0734. Epub 2022 Jul 15. PMID: 36061155; PMCID: PMC9399579.

35: Katsanos G, Karakasi KE, Antoniadis N, Vasileiadou S, Kofinas A, Morsi- Yeroyannis A, Michailidou E, Goulis I, Sinakos E, Giouleme O, Oikonomou IM, Evlavis G, Tsakiris G, Massa E, Mouloudi E, Tsoulfas G. Enhanced recovery after surgery in liver transplantation: Challenges and feasibility. World J Transplant. 2022 Jul 18;12(7):195-203. doi: 10.5500/wjt.v12.i7.195. PMID: 36051455; PMCID: PMC9331408.

36: Sinakos E, Panas P, Fragkou N, Antoniadis N, Katsanos G, Tsakni E, Oikonomou T, Notopoulos A, Tsoulfas G, Goulis I, Akriviadis E. Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease. Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):331-337. doi: 10.51821/85.2.9577. PMID: 35709777.

37: Papagiouvanni I, Theodorakopoulou MP, Sarafidis PA, Sinakos E, Goulis I. Peripheral endothelial and microvascular damage in liver cirrhosis: A systematic review and meta-analysis. Microcirculation. 2022 Jul;29(4-5):e12773. doi: 10.1111/micc.12773. Epub 2022 Jun 19. PMID: 35652811.

38: Sinakos E, Liava C, Loomba R. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. Ann Gastroenterol. 2022 May-Jun;35(3):213-225. doi: 10.20524/aog.2022.0704. Epub 2022 Apr 7. PMID: 35599922; PMCID: PMC9062842.

39: Arelaki S, Koletsa T, Sinakos E, Papadopoulos V, Arvanitakis K, Skendros P, Akriviadis E, Ritis K, Germanidis G, Hytiroglou P. Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis. Virchows Arch. 2022 Sep;481(3):455-465. doi: 10.1007/s00428-022-03330-7. Epub 2022 May 3. PMID: 35503185.

40: Chatziioannou A, Georgopoulou V, Katsiki E, Sinakos E. Primary hepatic neuroendocrine tumor treated with liver transplantation. Dig Liver Dis. 2022 Oct;54(10):1441-1443. doi: 10.1016/j.dld.2022.01.133. Epub 2022 Feb 12. PMID: 35168876.

41: Liava C, Sinakos E. Semaglutide for nonalcoholic steatohepatitis: closer to a solution? Hepatobiliary Surg Nutr. 2021 Aug;10(4):541-544. doi: 10.21037/hbsn-21-231. PMID: 34430539; PMCID: PMC8351017.

42: Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol. 2021 Jul 21;27(27):4252-4275. doi: 10.3748/wjg.v27.i27.4252. PMID: 34366604; PMCID: PMC8316913.

43: Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101568. doi: 10.1016/j.clinre.2020.10.012. Epub 2020 Dec 11. PMID: 33309563.

44: Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. PMID: 33185364.

45: Protopapas AA, Papagiouvanni I, Fragkou N, Alevroudis E, Sinakos E, Goulis I. Estimation of glomerular filtration rate in patients with cirrhosis: evaluation of equations currently used in clinical practice and validation of Royal Free Hospital cirrhosis glomerular filtration rate. Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):84-91. doi: 10.1097/MEG.0000000000001935. PMID: 32956187.

46: Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol. 2020 Mar-Apr;19(2):134-144. doi: 10.1016/j.aohep.2019.07.013. Epub 2019 Sep 23. PMID: 31606352.

47: Gioula G, Sinakos E, Gigi E, Goulis I, Vasiliadis T, Minti F, Akriviadis E. 'Distribution of Hepatitis C Virus genotypes in northern Greece in the last decade: descriptive analysis and clinical correlations'. Glob Health Epidemiol Genom. 2019 Sep 2;4:e5. doi: 10.1017/gheg.2019.4. PMID: 31516719; PMCID: PMC6719250.

48: Sinakos E, Hytiroglou P, Stachteas P, Liava C, Akriviadis E. The significance of paired biopsies in estimating disease progression in patients with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):897-898. doi: 10.1097/MEG.0000000000001412. PMID: 31149958.

49: Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol. 2018 Nov 27;10(11):790-794. doi: 10.4254/wjh.v10.i11.790. PMID: 30533179; PMCID: PMC6280165.

50: Kalogirou M, Chourmouzi D, Dedes I, Kiapidou S, Akriviadis E, Sinakos E. Transarterial embolization for the treatment of complicated liver hemangiomas: A report of two cases and review of the literature. Clin Mol Hepatol. 2018 Sep;24(3):345-349. doi: 10.3350/cmh.2017.0075. Epub 2018 Jun 11. PMID: 29886705; PMCID: PMC6166110.

51: Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O'Grady JG, Akriviadis E, Sinakos E, Carithers RL Jr, Ramond MJ, Maddrey WC, Morgan TR, Duhamel A, Mathurin P. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology. 2018 Aug;155(2):458-468.e8. doi: 10.1053/j.gastro.2018.05.011. Epub 2018 May 5. PMID: 29738698.

52: Soulaidopoulos S, Sinakos E, Dimopoulou D, Vettas C, Cholongitas E, Garyfallos A. Anticholinergic syndrome induced by toxic plants. World J Emerg Med. 2017;8(4):297-301. doi: 10.5847/wjem.j.1920-8642.2017.04.009. PMID: 29123609; PMCID: PMC5675972.

53: Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct- acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol. 2017 Jul;178(1):130-136. doi: 10.1111/bjh.14640. Epub 2017 Apr 25. PMID: 28439915.

54: Sousos N, Sinakos E, Klonizakis P, Adamidou D, Daniilidis A, Gigi E, Vetsiou E, Tsioni K, Mandala E, Vlachaki E. Deferasirox improves liver fibrosis in beta- thalassaemia major patients. A five-year longitudinal study from a single thalassaemia centre. Br J Haematol. 2018 Apr;181(1):140-142. doi: 10.1111/bjh.14509. Epub 2017 Jan 20. PMID: 28106901.

55: Cholongitas E, Ioannidou M, Goulis I, Chalevas P, Ntogramatzi F, Athanasiadou Z, Notopoulos A, Alevroudis M, Sinakos E, Akriviadis E. Comparison of creatinine and cystatin formulae with ⁵¹ Chromium- ethylenediaminetetraacetic acid glomerular filtration rate in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2017 Jan;32(1):191-198. doi: 10.1111/jgh.13446. PMID: 27177318.

56: Akriviadis E, Sinakos E. Treatment of alcoholic hepatitis: is this a "dead- end"? Ann Gastroenterol. 2016 Apr-Jun;29(2):236-7. doi: 10.20524/aog.2016.0023. PMID: 27065743; PMCID: PMC4805751.

57: Sinakos E, Antoniadis N, Goulis I, Cholongitas E, Kiapidou S, Tsakni E, Vasiliadis T, Papanikolaou V, Akriviadis E. Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels. Ann Gastroenterol. 2016 Apr-Jun;29(2):208-13. doi: 10.20524/aog.2016.0014. PMID: 27065734; PMCID: PMC4805742.

58: Gbandi E, Goulas A, Sevastianos V, Hadziyannis S, Panderi A, Koskinas J, Papatheodoridis G, Vasiliadis T, Agapakis D, Protopapas A, Ioannidou P, Zacharakis G, Sinakos E, Koutsounas S, Germanidis G. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. Pharmacol Rep. 2016 Apr;68(2):476-82. doi: 10.1016/j.pharep.2015.10.009. Epub 2015 Nov 6. PMID: 26922556.

59: Manolakopoulos S, Kranidioti H, Goulis J, Vlachogiannakos J, Elefsiniotis J, Kouroumalis EA, Koskinas J, Kontos G, Evangelidou E, Doumba P, Sinakos E, Vafiadou Ι, Koulentaki M, Papatheodoridis G, Akriviadis E. Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. Ann Gastroenterol. 2015 Oct-Dec;28(4):481-6. PMID: 26423714; PMCID: PMC4585396.

60: Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E. Authors' reply. Ann Gastroenterol. 2015 Oct-Dec;28(4):507. PMID: 26423354; PMCID: PMC4585406.

61: Sinakos E, Hytiroglou P, Chourmouzi D, Akriviadis E. Focal nodular hyperplasia in an individual with Abernethy malformation type 1b. Dig Liver Dis. 2015 Dec;47(12):1089. doi: 10.1016/j.dld.2015.07.046. Epub 2015 Aug 6. PMID: 26341965.

62: Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E. Antiviral therapy leads to histological improvement of HBeAg- negative chronic hepatitis B patients. Ann Gastroenterol. 2015 Jul- Sep;28(3):374-378. PMID: 26126929; PMCID: PMC4480175.

63: Papalavrentios L, Sinakos E, Chourmouzi D, Hytiroglou P, Drevelegas K, Constantinides M, Drevelegas A, Talwalkar J, Akriviadis E. Value of 3 Tesla diffusion-weighted magnetic resonance imaging for assessing liver fibrosis. Ann Gastroenterol. 2015 Jan-Mar;28(1):118-123. PMID: 25608776; PMCID: PMC4289984.

64: Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014 Apr 27;6(4):178-87. doi: 10.4254/wjh.v6.i4.178. PMID: 24799986; PMCID: PMC4009473.

65: Gigi E, Sykia A, Sinakos E, Koumerkeridis G, Raptopoulou-Gigi M, Bellou A, Mougiou D, Orfanou E, Vrettou E. Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis. Hippokratia. 2012 Oct;16(4):342-6. PMID: 23935314; PMCID: PMC3738609.

66: Treeprasertsuk S, Björnsson E, Sinakos E, Weeding E, Lindor KD. Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. World J Gastrointest Pharmacol Ther. 2013 Aug 6;4(3):61-8. doi: 10.4292/wjgpt.v4.i3.61. PMID: 23919218; PMCID: PMC3729869.

67: Sinakos E, Samuel S, Enders F, Loftus EV Jr, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr;19(5):1004-9. doi: 10.1097/MIB.0b013e3182802893. PMID: 23502353.

68: Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, Zouridakis K, Bellou AL, Orfanou E, Raptopoulou-Gigi M. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med. 2013 Jan-Feb;7(1):52-7. doi: 10.1097/ADM.0b013e318279756f. PMID: 23340710.

69: Papalavrentios L, Sinakos E, Chourmouzi D, Hytiroglou P, Drevelegas K, Drevelegas A, Akriviadis E. 3 Tesla diffusion-weighted MRI for assessing liver fibrosis in nonalcoholic fatty liver disease. Hepatology. 2013 Jul;58(1):449-50. doi: 10.1002/hep.26220. PMID: 23299663.

70: Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; PARC Study Group. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders. Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1012-9. doi: 10.1097/MEG.0b013e3283557e23. PMID: 22668876.

71: Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012 Jul;27(7):1150-8. doi: 10.1111/j.1440-1746.2012.07109.x. PMID: 22413872.

72: Sinakos E, Vlachaki E, Tsapas A. Safety of deferasirox in sickle cell disease patients with co-existing liver impairment. Br J Haematol. 2012 May;157(4):505-6; author reply 506-7. doi: 10.1111/j.1365-2141.2012.09040.x. Epub 2012 Feb 2. PMID: 22299817.

73: Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012 May;32(5):790-5. doi: 10.1111/j.1478-3231.2011.02678.x. Epub 2011 Dec 4. PMID: 22136310.

74: Sinakos E, Papalavrentios L, Chourmouzi D, Dimopoulou D, Drevelegas A, Akriviadis E. The clinical presentation of Von Meyenburg complexes. Hippokratia. 2011 Apr;15(2):170-3. PMID: 22110302; PMCID: PMC3209683.

75: Imam MH, Silveira MG, Sinakos E, Gossard AA, Jorgensen R, Keach J, DeCook AC, Lindor KD. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Feb;10(2):182-5. doi: 10.1016/j.cgh.2011.09.013. Epub 2011 Oct 1. PMID: 21963959.

76: Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011 Nov;34(10):1185-92. doi: 10.1111/j.1365-2036.2011.04863.x. Epub 2011 Sep 29. PMID: 21957881; PMCID: PMC3752281.

77: Paschos P, Vlachaki E, Pasvanti C, Sinakos E, Kalpaka A, Klonizakis P, Perifanis V. Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience. Acta Haematol. 2011;126(4):231-3. doi: 10.1159/000330516. Epub 2011 Sep 21. PMID: 21934299.

78: Sinakos E, Abbas G, Jorgensen RA, Lindor KD. Serum lipids in primary sclerosing cholangitis. Dig Liver Dis. 2012 Jan;44(1):44-8. doi: 10.1016/j.dld.2011.07.020. Epub 2011 Sep 3. PMID: 21890438.

79: Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. High- dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10. PMID: 21556038; PMCID: PMC3168684.

80: Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011 May;9(5):434-9.e1. doi: 10.1016/j.cgh.2011.02.007. Epub 2011 Feb 17. PMID: 21334457.

81: Sinakos E, Selvaggi G, Papalavrentios L, Tzakis A, Akriviadis E. The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence. Ann Gastroenterol. 2011;24(3):228-230. PMID: 24713719; PMCID: PMC3959316.

82: Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011 Jan;9(1):52-6. doi: 10.1016/j.cgh.2010.09.020. Epub 2010 Oct 1. PMID: 20920596.

83: Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD. Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol. 2011 Aug;45(7):e66-71. doi: 10.1097/MCG.0b013e3181f18c4e. PMID: 20856137.

84: Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):473-88. doi: 10.1586/egh.10.33. PMID: 20678020.

85: Sinakos E, Gigi E, Lalla T, Bellou AL, Sykja A, Orphanou E, Vrettou E, Tsapas V, Raptopoulou M. Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. Hippokratia. 2010 Apr;14(2):122-5. PMID: 20596269; PMCID: PMC2895284.

86: Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology. 2010 Jul;52(1):197-203. doi: 10.1002/hep.23631. PMID: 20564380; PMCID: PMC2928060.

87: Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol. 2010 Aug;105(8):1762-9. doi: 10.1038/ajg.2010.186. Epub 2010 May 11. PMID: 20461068.

88: Fotiadu A, Gagalis A, Akriviadis E, Kotoula V, Sinakos E, Karkavelas G, Hytiroglou P. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol Int. 2010 Feb;60(2):87-92. doi: 10.1111/j.1440-1827.2009.02489.x. PMID: 20398192.

89: Sinakos E, Perifanis V, Vlachaki E, Tsatra I, Raptopoulou-Gigi M. Is liver stiffness really unrelated to liver iron concentration? Br J Haematol. 2010 Jul;150(2):247-8. doi: 10.1111/j.1365-2141.2010.08183.x. Epub 2010 Apr 4. PMID: 20377588.

90: Sinakos E, Lindor KD. Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy? Am J Gastroenterol. 2010 Mar;105(3):596-8. doi: 10.1038/ajg.2009.639. PMID: 20203641.

91: Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335. PMID: 20113152.

92: Chourmouzi D, Sinakos E, Papalavrentios L, Akriviadis E, Drevelegas A. Gastrointestinal stromal tumors: a pictorial review. J Gastrointestin Liver Dis. 2009 Sep;18(3):379-83. PMID: 19795038.

93: Sykia A, Gigi E, Sinakos E, Bibashi E, Bellou A, Raptopoulou-Gigi M. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg- interferon-a and ribavirin. J Gastrointestin Liver Dis. 2009 Mar;18(1):118-9. PMID: 19337648.

94: Televantou D, Sinakos E, Akriviadis EA, Hytiroglou P. Toxic hepatic injury mimicking ascending cholangitis: is Pyrus amygdaliformis to blame? Virchows Arch. 2008 Oct;453(4):413-5. doi: 10.1007/s00428-008-0663-0. Epub 2008 Sep 12. PMID: 18787839.

95: Gigi E, Raptopoulou-Gigi M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, Lalla TH, Sinakos E, Tsapas V. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat. 2008 Feb;15(2):145-54. doi: 10.1111/j.1365-2893.2007.00908.x. PMID: 18184198.

96: Gigi E, Sinakos E, Lalla T, Vrettou E, Orphanou E, Raptopoulou M. Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. Hippokratia. 2007 Oct;11(4):196-8. PMID: 19582193; PMCID: PMC2552983.

97: Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M. Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece. J Gastrointestin Liver Dis. 2007 Mar;16(1):19-22. PMID: 17410284.